Tiziana Life Sciences Ltd
No SEC Form 4 filings for $TLSA in the last 30 days.
See all $TLSA insider activity →Tiziana Life Sciences (TLSA) completed patient visits in its Phase 2a trial for intranasal foralumab in non-active secondary progressive multiple sclerosis. The trial enrolled 48 patients and aims to evaluate safety, tolerability, and efficacy. The company expects to announce topline data in October. Foralumab is Tiziana's lead development candidate.
Aethlon Medical (AEMD) surged 360% after announcing a merger with North Immunology and a $180M private placement. Tiziana Life Sciences (TLSA) rose 22% due to a clinical trial collaboration. Capricor Therapeutics (CAPR) gained 9% with upcoming Duchenne data. Firefly Neuroscience (AIFF) climbed 26% after a brain-medicine partnership. Clearmind Medicine (CMND) increased 6% following an FDA psychedelic hearing.
Tiziana Life Sciences (TLSA) announced a clinical trial collaboration to test intranasal foralumab with anti-CD20 therapy for RRMS patients. The company has no revenue, a GF Score of 23/100, and $1.0M in insider purchases over 12 months. TLSA's market cap is approximately $103M.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning TLSA (Tiziana Life Sciences Ltd). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent TLSA coverage spans financial news, technology and market movers.
Positive trial completion may reduce downside risk and set up a potential upside if data are favorable.
Collaboration could expand Tiziana's MS pipeline and address unmet patient needs.
The MOU could advance TLSA's pipeline and potentially boost the stock if trial data are positive.
Potential expansion of foralumab pipeline could boost valuation if trial shows efficacy.
Analyst upgrade may boost price.
AlphAI scores every news story that mentions TLSA with an AI model for sentiment and relevance, and aggregates insider trades from Tiziana Life Sciences Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
Tiziana Life Sciences (TLSA) completed patient visits in its Phase 2a trial for intranasal foralumab in non-active secondary progressive multiple sclerosis. The trial enrolled 48 patients and aims to evaluate safety, tolerability, and efficacy. The company expects to announce topline data in October. Foralumab is Tiziana's lead development candidate.
2 min readAethlon Medical (AEMD) surged 360% after announcing a merger with North Immunology and a $180M private placement. Tiziana Life Sciences (TLSA) rose 22% due to a clinical trial collaboration. Capricor Therapeutics (CAPR) gained 9% with upcoming Duchenne data. Firefly Neuroscience (AIFF) climbed 26% after a brain-medicine partnership. Clearmind Medicine (CMND) increased 6% following an FDA psychedelic hearing.
3 min readTiziana Life Sciences (TLSA) announced a clinical trial collaboration to test intranasal foralumab with anti-CD20 therapy for RRMS patients. The company has no revenue, a GF Score of 23/100, and $1.0M in insider purchases over 12 months. TLSA's market cap is approximately $103M.
2 min readTiziana Life Sciences (TLSA) signed an MOU with King Abdullah International Medical Research Center to collaborate on a clinical trial for relapsing-remitting multiple sclerosis using intranasal foralumab. The trial will combine foralumab with existing anti-CD20 therapy. Tiziana's CEO, Ivor Elrifi, noted this does not change their ongoing Phase 2 trial for non-active secondary progressive multiple sclerosis, with results expected in October 2026.
2 min readTiziana Life Sciences (TLSA) received a Buy rating and $7 price target from BTIG. Ocean Power Technologies (OPTT) is using Palantir Foundry to improve operations. Sintana Energy (SEI) reported TotalEnergies' acquisition of a 40% interest in Namibia’s PEL 83. American Resources (AREC) joined the Critical Minerals Institute. Thistle Resources (TRCG) launched a Phase 3 drill program. BioHarvest Sciences (BHST) plans to dual-list on the Tel Aviv Stock Exchange. Alvopetro Energy (ALV) reported August
3 min readBTIG initiated coverage of Tiziana Life Sciences (TLSA) with a Buy rating and $7 price target, citing its Treg-based approach to treating neurodegenerative diseases. The company's foralumab nasal spray aims to reduce CNS inflammation, with promising imaging data in SPMS, MSA, and Alzheimer's. BTIG highlighted the INFORM-MS trial as a key near-term catalyst.
2 min readTiziana Life Sciences (TLSA) will present Phase 2a BANYAN trial data on intranasal foralumab for ALS at ALS Nexus 2026. The trial, conducted via the Healey ALS MyMatch program, aims to assess safety, biomarkers, and clinical effects. TLSA's stock closed at $1.14, up 1.79%, and is up 1.15% in pre-market trading.
1 min readJefferies says Parkinson’s drug development is shifting toward neuroinflammation, while still pursuing alpha-synuclein. It estimates the addressable early US and EU population could exceed 2 million by 2035, implying a ~$8 billion disease-modifying therapy market. It cites Roche’s prasinezumab missed endpoints twice but moved to Phase III, and Denali’s BIIB122 failed broadly. Companies mentioned include Ventyx (VTYX), BioVie (BIVI), and Tiziana (TLSA).
7 min readElrifi Ivor (Chief Executive Officer) purchased 321,423 indirectly-held shares of Tiziana Life Sciences Ltd (TLSA) at an average of $0.99 ($0.97–$1.00, $0.32M total) across 2 trades over 2026-08-04 to 2026-08-05.
2 min readElrifi Ivor (Chief Executive Officer) purchased 667,000 indirectly-held shares of Tiziana Life Sciences Ltd (TLSA) at $1.00 ($0.67M total) on 2026-08-03.
2 min read